Diabetes Drug Avandia Still Causing Debate
Coverage on the popular GlaxoSmithKline medicine, Avandia, has recently sparked due to a new Senate report. Although hundreds of individuals suffer each month from the dangerous side affects associated with the drug, the drug still remains on the market. A better look at these latest developments can be read in this NY Times article - "Research Ties Diabetes Drug to Heart Woes".
Shawn Khorrami and James Kenna of KPA have been appointed to the JCCP Steering Committee for Avandia, and will continue to fight on behalf of those injured individuals.
